Page 23 - Company Codes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Jul 29, 2021   NEW YORK, July 29, 2021 /PRNewswire/ Oramed Pharmaceuticals Inc.  (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Michael Rabinowitz to the newly created position of Chief Commercial Officer effective August 1, 2021. Mr. Rabinowitz will be responsible for Oramed s overall commercial strategy and execution. As we move through the Phase III trials of our oral insulin, ORMD-0801, we are looking ahead towards the next step:  commercialization. We re very pleased to welcome Michael Rabinowitz as Oramed s first Chief Commercial Officer. Michael s years of global commercial experience make him the ideal leader for Oramed s next phase of growth and development. Throughout his career, he has built a strong track record in successfully launching new products and will certainly play a vital role in commercializing Oramed

United statesNadav kidronJosh hexterMichael rabinowitzOramed pharmaceuticals incCompany contactMerck coOramed pharmaceuticalsCarlson school of managementExchange commissionHarvard business schoolPrnewswire oramed pharmaceuticals incCompany codesUniversity of minnesotaOramed pharmaceuticals nasdaqChief commercial officer